NEWS

Alliance Announces FDA Acceptance of Supplemental Biologics License Application Supported by Results from the Phase III ATOMIC Trial for Patients with Stage III dMMR Colon Cancer

June 11, 2026 - The Alliance for Clinical Trials in Oncology (Alliance) today announced that the U.S. Food and Drug Administration has accepted for review Genentech’s supplemental Biologic License Application for their immunotherapy drug atezolizumab (Tecentriq®) for the treatment of patients with


Alliance Digital Tool Proves Effective at Keeping Patients Engaged in Trials

June 8, 2026 - In a step forward for patient-centered cancer research, a new pilot project reveals that 84% of participants had a positive experience using a newly developed online tool created by the Alliance for Clinical Trials in Oncology called the Participant Engagement Portal (PEP). Alliance created PEP to foster direct connection between cancer researchers and the individuals who volunteer for clinica


Alliance Trial to Study a Targeted Radiation Approach After Lung Cancer Surgery
Recently activated phase II clinical trial will evaluate post‑operative radiation in non-small cell lung cancer

May 19, 2026 - The Alliance for Clinical Trials in Oncology has launched a new clinical research study to explore whether a more targeted form of radiation therapy lowers the chance of lung cancer returning after surgery. The study (Alliance A082402) is for people with non‑small cell lung cancer (N


Older News